Publications

Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell Immunotherapies

Download PDF
Resource: Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell Immunotherapies

.

Related Articles

Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer

Link

Spatially resolved ex vivo drug response profiling in SMARCB1-deficient sinonasal carcinoma

Link